Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Relationship between Exposure of (–)-N-{2-[(R)-3-(6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)piperidino]ethyl}-4-fluorobenzamide (YM758), a “Funny” If Current Channel Inhibitor, and Heart Rate Reduction in Tachycardia-Induced Beagle Dogs

Ken-ichi Umehara, Kouichi Wada, Kiyoshi Noguchi, Takafumi Iwatsubo, Takashi Usui and Hidetaka Kamimura
Drug Metabolism and Disposition July 2009, 37 (7) 1427-1433; DOI: https://doi.org/10.1124/dmd.108.026385
Ken-ichi Umehara
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kouichi Wada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kiyoshi Noguchi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takafumi Iwatsubo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takashi Usui
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hidetaka Kamimura
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

(–)-N-{2-[(R)-3-(6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)piperidino]ethyl}-4-fluorobenzamide (YM758), a novel “funny” If current channel (If channel) inhibitor, is developed as a treatment for stable angina and atrial fibrillation. In this study, the pharmacokinetic/pharmacodynamic (PK/PD) relationship after intravenous administration of YM758 to tachycardia-induced dogs was investigated and described based on the simplified compartment model. The PK of YM758 in dogs did not differ between the nontreated and tachycardia-induced groups. A drug-induced reduction in heart rate (HR) was clearly observed, and the half-life of the duration of the effect (approximately 4.0 h) was longer than that of the plasma concentration of the unchanged drug. The fitting and simulation procedure from the PK/PD relationship between the time profiles for YM758 plasma concentration and HR reduction had an ECe50 value (YM758 concentration in the effective compartment resulting in a 50% decrease of the maximum effect) of 6.0 ng/ml, which did not agree with the results of the in vitro experiment using right atria isolated from guinea pigs (EC30, 70.4 ng/ml). In addition, in the in vitro experiments, YM758 metabolites had a weak inhibitory effect, if any, on the spontaneous beat rate of the right atria from guinea pigs. These data, along with the previous finding that YM758 and its metabolites are eliminated rapidly from rat hearts, indicate that the duration of the pharmacological effect of YM758 (compared with the rapid elimination of the plasma drug concentration) may be the result of strong binding and/or slower dissociation of YM758 in the If channel. Such PK/PD analyses allow the pharmacological profiles of many drugs, especially cardiovascular drugs, to be more readily understood and better predicted during the clinical stages.

Footnotes

  • Article, publication date, and citation information can be found at http://dmd.aspetjournals.org.

  • doi:10.1124/dmd.108.026385.

  • ABBREVIATIONS: HR, heart rate; If channel, “funny” If current channel; YM758, (–)-N-{2-[(R)-3-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)piperidino]ethyl}-4-fluorobenzamide; PK, pharmacokinetics; PD, pharmacodynamics; MIC, minimum inhibitory concentration; Cmax, maximum plasma concentration; AUC, area under the curve; ECG, electrocardiogram; YM-344540, deuterium [d4]-labeled YM758 monophosphate; kel, terminal elimination rate constant; t1/2, elimination half-life; AUCinf, area under the curve extrapolated to infinity; CLtot, total body clearance; Vdss, distribution volume at the steady state; SBR, spontaneous beat rate; YM-234903, (3R-1-{2-[(4-fluorobenzoyl)amino]ethyl} piperidine-3-carboxylic acid; YM-252124, 6,7-dimethoxy-2-[(3R)-piperidin-3-ylcarbonyl]-1,2,3,4-tetrahydroisoquinoline; YM-385459, (5R)-5-[(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)carbonyl]piperidin-2-one; YM-385461, N-(4-fluorobenzoyl)glycine; YM-385462 (chiral relation to YM-385463), 4-fluoro-N-(2-{(3R)-3-[(4-hydroxy-6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)carbonyl]piperidin-1-yl}ethyl)benzamide; YM-385463 (chiral relation to YM-385462), 4-fluoro-N-(2-{(3R)-3-[(4-hydroxy-6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)carbonyl]piperidin-1-yl}ethyl)benzamide; YM-388288 (racemate of YM-385462 and YM-385463), 4-fluoro-N-(2-{(3R)-3-[(4-hydroxy-6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H-yl)carbonyl]piperidin-1-yl}ethyl)benzamide; YM-394111, 4-fluoro-N-(2-{(3R)-3-[(6-hydroxy-7-methoxy-3,4-dihydroisoquinolin-2(1H)-yl)carbonyl]piperidin-1-yl}ethyl)benzamide; YM-394112, 4-fluoro-N-(2-{(3R)-3-[(7-hydroxy-6-methoxy-3,4-dihydroisoquinolin-2(1H)-yl)carbonyl]piperidin-1-yl}ethyl)benzamide; YM-396944, 2-[2-({[(3R)-1-{2-[(4-fluorobenzoyl)amino]ethyl}piperidin-3-yl]carbonyl}amino)ethyl]-4,5-dimethoxybenzoic acid.

    • Accepted April 7, 2009.
    • Received December 21, 2008.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 37 (7)
Drug Metabolism and Disposition
Vol. 37, Issue 7
1 Jul 2009
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Relationship between Exposure of (–)-N-{2-[(R)-3-(6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)piperidino]ethyl}-4-fluorobenzamide (YM758), a “Funny” If Current Channel Inhibitor, and Heart Rate Reduction in Tachycardia-Induced Beagle Dogs
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Relationship between Exposure of (–)-N-{2-[(R)-3-(6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)piperidino]ethyl}-4-fluorobenzamide (YM758), a “Funny” If Current Channel Inhibitor, and Heart Rate Reduction in Tachycardia-Induced Beagle Dogs

Ken-ichi Umehara, Kouichi Wada, Kiyoshi Noguchi, Takafumi Iwatsubo, Takashi Usui and Hidetaka Kamimura
Drug Metabolism and Disposition July 1, 2009, 37 (7) 1427-1433; DOI: https://doi.org/10.1124/dmd.108.026385

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Relationship between Exposure of (–)-N-{2-[(R)-3-(6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)piperidino]ethyl}-4-fluorobenzamide (YM758), a “Funny” If Current Channel Inhibitor, and Heart Rate Reduction in Tachycardia-Induced Beagle Dogs

Ken-ichi Umehara, Kouichi Wada, Kiyoshi Noguchi, Takafumi Iwatsubo, Takashi Usui and Hidetaka Kamimura
Drug Metabolism and Disposition July 1, 2009, 37 (7) 1427-1433; DOI: https://doi.org/10.1124/dmd.108.026385
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • TMDD Affects PK of IL-10 Fc-fusion Proteins
  • Uptake as the RDS in Pevonedistat Hepatic Clearance
  • In vitro downregulation of OATP1B1 by retinoids
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics